A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody

Purpose To review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin gene-related peptide antibodies. Overview Calcitonin gene-related peptide has been implicated in the pathophysiology of migraine. Galcanezumab is an ant...

Full description

Saved in:
Bibliographic Details
Published inCephalalgia Vol. 39; no. 10; pp. 1284 - 1297
Main Authors Kielbasa, William, Helton, Danielle L
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.09.2019
Subjects
Review
pharmacokinetics
antibody
CGRP
Migraine
pharmacodynamics
galcanezumab
Online AccessGet full text

Cover

Abstract Purpose To review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin gene-related peptide antibodies. Overview Calcitonin gene-related peptide has been implicated in the pathophysiology of migraine. Galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide. Other antibodies that target calcitonin gene-related peptide include eptinezumab and fremanezumab. To understand how antibodies can affect the extent and duration of free ligand concentrations, it is important to consider the dose and pharmacokinetics of an antibody, and the kinetics of the ligand and antibody–ligand complex. Insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided. Discussion Antibodies are administered parenterally because oral absorption is limited by gastrointestinal degradation and inefficient diffusion through the epithelium. The systemic absorption of antibodies following intramuscular or subcutaneous administration most likely occurs via convective transport through lymphatic vessels into blood. The majority of antibody elimination occurs via intracellular catabolism into peptides and amino acids following endocytosis. Binding of ligand to an antibody reduces the free ligand that is available to interact with the receptor and efficacy is driven by the magnitude and duration of the reduction in free ligand concentration. A galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing. The model provides evidence for a mechanistic linkage to galcanezumab therapeutic effects for the preventive treatment of migraine.
AbstractList Purpose To review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin gene-related peptide antibodies. Overview Calcitonin gene-related peptide has been implicated in the pathophysiology of migraine. Galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide. Other antibodies that target calcitonin gene-related peptide include eptinezumab and fremanezumab. To understand how antibodies can affect the extent and duration of free ligand concentrations, it is important to consider the dose and pharmacokinetics of an antibody, and the kinetics of the ligand and antibody–ligand complex. Insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided. Discussion Antibodies are administered parenterally because oral absorption is limited by gastrointestinal degradation and inefficient diffusion through the epithelium. The systemic absorption of antibodies following intramuscular or subcutaneous administration most likely occurs via convective transport through lymphatic vessels into blood. The majority of antibody elimination occurs via intracellular catabolism into peptides and amino acids following endocytosis. Binding of ligand to an antibody reduces the free ligand that is available to interact with the receptor and efficacy is driven by the magnitude and duration of the reduction in free ligand concentration. A galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing. The model provides evidence for a mechanistic linkage to galcanezumab therapeutic effects for the preventive treatment of migraine.
To review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin gene-related peptide antibodies.PURPOSETo review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin gene-related peptide antibodies.Calcitonin gene-related peptide has been implicated in the pathophysiology of migraine. Galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide. Other antibodies that target calcitonin gene-related peptide include eptinezumab and fremanezumab. To understand how antibodies can affect the extent and duration of free ligand concentrations, it is important to consider the dose and pharmacokinetics of an antibody, and the kinetics of the ligand and antibody-ligand complex. Insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.OVERVIEWCalcitonin gene-related peptide has been implicated in the pathophysiology of migraine. Galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide. Other antibodies that target calcitonin gene-related peptide include eptinezumab and fremanezumab. To understand how antibodies can affect the extent and duration of free ligand concentrations, it is important to consider the dose and pharmacokinetics of an antibody, and the kinetics of the ligand and antibody-ligand complex. Insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.Antibodies are administered parenterally because oral absorption is limited by gastrointestinal degradation and inefficient diffusion through the epithelium. The systemic absorption of antibodies following intramuscular or subcutaneous administration most likely occurs via convective transport through lymphatic vessels into blood. The majority of antibody elimination occurs via intracellular catabolism into peptides and amino acids following endocytosis. Binding of ligand to an antibody reduces the free ligand that is available to interact with the receptor and efficacy is driven by the magnitude and duration of the reduction in free ligand concentration. A galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing. The model provides evidence for a mechanistic linkage to galcanezumab therapeutic effects for the preventive treatment of migraine.DISCUSSIONAntibodies are administered parenterally because oral absorption is limited by gastrointestinal degradation and inefficient diffusion through the epithelium. The systemic absorption of antibodies following intramuscular or subcutaneous administration most likely occurs via convective transport through lymphatic vessels into blood. The majority of antibody elimination occurs via intracellular catabolism into peptides and amino acids following endocytosis. Binding of ligand to an antibody reduces the free ligand that is available to interact with the receptor and efficacy is driven by the magnitude and duration of the reduction in free ligand concentration. A galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing. The model provides evidence for a mechanistic linkage to galcanezumab therapeutic effects for the preventive treatment of migraine.
To review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin gene-related peptide antibodies. Calcitonin gene-related peptide has been implicated in the pathophysiology of migraine. Galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide. Other antibodies that target calcitonin gene-related peptide include eptinezumab and fremanezumab. To understand how antibodies can affect the extent and duration of free ligand concentrations, it is important to consider the dose and pharmacokinetics of an antibody, and the kinetics of the ligand and antibody-ligand complex. Insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided. Antibodies are administered parenterally because oral absorption is limited by gastrointestinal degradation and inefficient diffusion through the epithelium. The systemic absorption of antibodies following intramuscular or subcutaneous administration most likely occurs via convective transport through lymphatic vessels into blood. The majority of antibody elimination occurs via intracellular catabolism into peptides and amino acids following endocytosis. Binding of ligand to an antibody reduces the free ligand that is available to interact with the receptor and efficacy is driven by the magnitude and duration of the reduction in free ligand concentration. A galcanezumab pharmacokinetic/pharmacodynamic model shows that galcanezumab decreases free calcitonin gene-related peptide concentrations in a dose- and time-dependent manner and continues to suppress free calcitonin gene-related peptide with repeated dosing. The model provides evidence for a mechanistic linkage to galcanezumab therapeutic effects for the preventive treatment of migraine.
Author Helton, Danielle L
Kielbasa, William
Author_xml – sequence: 1
  givenname: William
  surname: Kielbasa
  fullname: Kielbasa, William
  email: wkielbasa@lilly.com
  organization: Eli Lilly and Company, Indianapolis, IN, USA
– sequence: 2
  givenname: Danielle L
  surname: Helton
  fullname: Helton, Danielle L
  organization: Eli Lilly and Company, Indianapolis, IN, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30917684$$D View this record in MEDLINE/PubMed
BookMark eNp9kcFvFCEUxompsdvq3ZPh6MFRGCgzeDBpNraaNLExeiZvGNilzsAKTJv13_AfLuPuGm2iJ-C93_e9PL4TdOSDNwg9p-Q1pU3zhjDGKKk5lS0nTUseoQXloq1q2dZHaDG3q7l_jE5SuiGEnAkinqBjRiRtRMsX6Oc59uYOmwjYhohHt4rgvHmLr9cQR9DhW3llpzH4Hm_2tX7rYSw155NbrXMqlxzwGHzQQ_AwFDi7LvTOJHzn8hrP5npKOHi8gkGDNz-mEbpXBfzFVsvLz9cH1fYpemxhSObZ_jxFXy_ef1l-qK4-XX5cnl9VmjOeK6ZBt40Fc2al1H3fUSEE6B64NIQLIwl0hdDcQvmczoq6YaRlne01sVYydore7Xw3UzeaXhufIwxqE90IcasCOPV3x7u1WoVbJRpKBOXF4OXeIIbvk0lZjS5pMwxlwTAlVVMpacsb2hb0xZ-zfg85JFEAsQN0DClFY5V2GbIL82g3KErUHLl6GHkRkgfCg_d_JNVOkmBl1E2YYgkt_Zu_BwUHvbo
CitedBy_id crossref_primary_10_1002_jcph_1511
crossref_primary_10_1186_s10194_021_01363_y
crossref_primary_10_7554_eLife_77146
crossref_primary_10_1007_s13311_022_01230_x
crossref_primary_10_1002_prp2_567
crossref_primary_10_1186_s10194_024_01724_3
crossref_primary_10_1007_s12325_021_01632_x
crossref_primary_10_1186_s12883_023_03203_9
crossref_primary_10_3988_jcn_2023_0311
crossref_primary_10_1186_s10194_022_01424_w
crossref_primary_10_1016_S1474_4422_20_30282_9
crossref_primary_10_1111_ene_15260
crossref_primary_10_1016_j_clineuro_2022_107355
crossref_primary_10_1016_j_neurol_2020_04_027
crossref_primary_10_1007_s40120_022_00410_3
crossref_primary_10_1186_s10194_024_01925_w
crossref_primary_10_1016_j_medidd_2020_100053
crossref_primary_10_1007_s00415_020_09707_5
crossref_primary_10_1002_brb3_2799
crossref_primary_10_1007_s40120_020_00214_3
crossref_primary_10_1186_s10194_020_01211_5
crossref_primary_10_1186_s10194_021_01230_w
crossref_primary_10_1056_NEJMoa2035908
crossref_primary_10_1007_s40122_024_00665_8
crossref_primary_10_2217_pmt_2020_0030
crossref_primary_10_1016_j_pharmthera_2023_108523
crossref_primary_10_1111_cts_70061
crossref_primary_10_3390_ijms241713471
crossref_primary_10_1007_s40120_023_00556_8
crossref_primary_10_1038_s41598_020_75602_8
crossref_primary_10_3390_ph14070700
crossref_primary_10_3389_fpain_2023_1130239
crossref_primary_10_1186_s10194_019_1018_8
crossref_primary_10_1111_head_14903
crossref_primary_10_1016_j_nwh_2023_06_004
crossref_primary_10_1111_head_13979
crossref_primary_10_1007_s40259_022_00530_0
crossref_primary_10_1080_14740338_2022_2130890
crossref_primary_10_1177_03331024231161261
crossref_primary_10_1038_s41467_023_44083_4
crossref_primary_10_3390_jcm13071964
crossref_primary_10_2147_JPR_S326905
crossref_primary_10_5604_01_3001_0014_5497
crossref_primary_10_3390_pharmaceutics15010293
crossref_primary_10_1007_s40265_020_01329_5
crossref_primary_10_1080_14740338_2023_2248877
crossref_primary_10_1111_head_13930
crossref_primary_10_1007_s00415_023_11788_x
crossref_primary_10_1111_head_13691
crossref_primary_10_1111_head_14062
crossref_primary_10_1111_ane_13599
crossref_primary_10_2174_1381612825666190709204107
Cites_doi 10.1208/s12248-014-9599-2
10.1097/WCO.0000000000000438
10.1016/j.tibtech.2006.04.001
10.1096/fj.201500078
10.1038/nrneurol.2010.127
10.4161/mabs.2.5.12833
10.1111/j.1365-2125.2009.03401.x
10.1007/s11095-017-2183-6
10.1016/j.pharmthera.2012.10.005
10.1208/s12248-009-9129-9
10.2165/11531280-000000000-00000
10.1208/s12248-010-9222-0
10.1007/s13311-018-0622-7
10.1038/256495a0
10.1016/S0165-5728(01)00242-9
10.1007/s40262-016-0417-0
10.1002/jcph.104
10.1203/00006450-198109000-00006
10.1111/apt.12507
10.1001/jamaneurol.2017.3859
10.1007/s40262-014-0208-4
10.1002/jps.20178
10.1016/S0140-6736(66)92190-8
10.1016/0167-0115(85)90013-8
10.1016/j.ophtha.2014.05.012
10.1007/s13311-013-0187-4
10.4155/bio.10.64
10.1208/s12248-013-9545-8
10.1093/brain/awx089
10.2165/00003088-200544040-00001
10.1016/j.clml.2015.12.007
10.1084/jem.20020400
10.1177/0333102418779543
10.1093/brain/aww096
10.1038/313054a0
10.1124/jpet.108.137703
10.1208/s12248-013-9517-z
10.1016/j.bcp.2005.12.041
10.1002/jcph.357
10.1111/j.1476-5381.2009.00190.x
10.4049/jimmunol.172.4.2021
10.1111/head.13379
10.1001/jamaneurol.2018.1212
10.1002/jcph.121
10.1007/BF01062336
10.1208/s12248-011-9251-3
10.1177/0091270004272731
10.1002/jcph.382
10.1016/j.ymeth.2005.01.001
10.1136/bmj.305.6864.1269
10.1007/BF01741594
10.1002/jcph.894
10.1002/jcph.140
10.1002/ana.410330109
10.1177/0091270009344989
10.1159/000235456
10.1021/mp300214k
10.1016/j.pain.2006.09.017
10.1111/j.1365-2125.2006.02803.x
10.1046/j.1468-2982.2000.00146.x
10.1002/9783527609628.ch3
10.1016/j.phrs.2016.07.015
10.1007/s40262-016-0452-x
10.3233/HAB-160306
10.1016/S1359-6446(05)03638-X
10.1007/s40259-016-0181-6
10.1007/s11739-016-1489-4
10.1016/j.yrtph.2014.12.002
10.1002/9783527609628.ch12
10.1093/ndt/gfh1092
10.1212/WNL.0000000000006640
10.1038/clpt.2008.170
10.1007/BF02786322
10.1016/0014-5793(85)80820-6
10.1016/0306-4522(88)90018-8
10.4049/jimmunol.166.5.3266
10.1016/0966-3274(95)80027-1
10.1177/0333102417747230
10.1212/WNL.86.16_supplement.S26.007
10.1016/j.pain.2003.09.008
10.1212/WNL.0b013e3182a6cb72
10.1208/s12248-009-9157-5
10.1177/0091270011413894
10.1016/0306-4522(90)90169-5
10.1177/0333102418771376
10.1002/ana.410280213
ContentType Journal Article
Copyright International Headache Society 2019
International Headache Society 2019 2019 International Headache Society
Copyright_xml – notice: International Headache Society 2019
– notice: International Headache Society 2019 2019 International Headache Society
DBID AFRWT
AAYXX
CITATION
NPM
7X8
5PM
DOI 10.1177/0333102419840780
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2982
EndPage 1297
ExternalDocumentID PMC6710614
30917684
10_1177_0333102419840780
10.1177_0333102419840780
Genre Journal Article
GroupedDBID ---
-TM
.2F
.2G
.3N
.GJ
.Y3
01A
0R~
1OC
29B
31S
31T
31Y
31~
36B
4.4
53G
54M
5GY
5RE
5VS
6PF
8-1
AABMB
AABOD
AACKU
AADUE
AAGGD
AAHHS
AAJIQ
AAJOX
AAJPV
AANSI
AAPEO
AAQDB
AAQXH
AARDL
AARIX
AASGM
AAWTL
AAXOT
AAYTG
AAZBJ
ABAWC
ABAWP
ABCCA
ABCQN
ABDBF
ABDWY
ABEIX
ABFWQ
ABHKI
ABIVO
ABJIS
ABJNI
ABKRH
ABNCE
ABPGX
ABQKF
ABQXT
ABRHV
ABVFX
ABVVC
ABYTW
ACARO
ACCFJ
ACDSZ
ACDXX
ACFMA
ACFYK
ACGBL
ACGFS
ACLHI
ACNXM
ACOFE
ACROE
ACRPL
ACUHS
ACXQS
ADBBV
ADEBD
ADEIA
ADMPF
ADNBR
ADNMO
ADOGD
ADSTG
ADTBJ
ADUKL
ADYCS
ADZOD
ADZYD
ADZZY
AECVZ
AEEZP
AENEX
AEQDE
AEQLS
AERKM
AEUHG
AEWDL
AEXFG
AEXNY
AFBPY
AFCOW
AFEBI
AFEET
AFKBI
AFKRG
AFRWT
AFUIA
AFVCE
AFWMB
AFZJQ
AGNHF
AGQPQ
AHEFC
AIGRN
AIWBW
AJABX
AJAOE
AJBDE
AJEFB
AJMMQ
AJSCY
AJUZI
AJXGE
ALMA_UNASSIGNED_HOLDINGS
ARTOV
ASPBG
AUTPY
AVWKF
AYAKG
AZFZN
B8M
B8O
B93
BDDNI
BFHJK
BKSCU
BSEHC
BYIEH
CAG
CBRKF
CDWPY
CFDXU
CO8
COF
CORYS
CQQTX
CS3
CUTAK
DC-
DC.
DC0
DC6
DCZOG
DD-
DD0
DE-
DOPDO
DU5
D~Y
EAD
EAP
EAS
EBC
EBD
EBS
EBX
ECV
EJD
EMB
EMK
EMOBN
ENC
EPT
ESX
F5P
FEDTE
FZ0
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HF~
HVGLF
HZI
HZ~
IHE
J8X
K.F
K.J
LH4
LW6
N9A
O9-
OIG
OVD
P.B
P2P
Q1R
Q7K
Q7R
Q7X
Q82
Q~Q
ROL
S01
SASJQ
SAUOL
SCDPB
SCNPE
SFC
SV3
TEORI
TUS
W99
WYUIH
YFH
ZGI
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
CITATION
AAEJI
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
NPM
7X8
5PM
ID FETCH-LOGICAL-c434t-3cac87fae5f99cddb1666acda49e046e90abac8c4fa407bf6273083bfdc0ff933
IEDL.DBID AFRWT
ISSN 0333-1024
1468-2982
IngestDate Thu Aug 21 18:36:48 EDT 2025
Fri Jul 11 15:35:15 EDT 2025
Mon Jul 21 06:03:06 EDT 2025
Tue Jul 01 05:32:05 EDT 2025
Thu Apr 24 23:04:37 EDT 2025
Tue Jun 17 22:46:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords pharmacokinetics
antibody
CGRP
Migraine
pharmacodynamics
galcanezumab
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c434t-3cac87fae5f99cddb1666acda49e046e90abac8c4fa407bf6273083bfdc0ff933
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://journals.sagepub.com/doi/full/10.1177/0333102419840780?utm_source=summon&utm_medium=discovery-provider
PMID 30917684
PQID 2199184718
PQPubID 23479
PageCount 14
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6710614
proquest_miscellaneous_2199184718
pubmed_primary_30917684
crossref_citationtrail_10_1177_0333102419840780
crossref_primary_10_1177_0333102419840780
sage_journals_10_1177_0333102419840780
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-09-01
PublicationDateYYYYMMDD 2019-09-01
PublicationDate_xml – month: 09
  year: 2019
  text: 2019-09-01
  day: 01
PublicationDecade 2010
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: Sage UK: London, England
PublicationTitle Cephalalgia
PublicationTitleAlternate Cephalalgia
PublicationYear 2019
Publisher SAGE Publications
Publisher_xml – name: SAGE Publications
References Glund, Stangier, van Ryn 2017; 56
Boxenbaum 1982; 10
Tabrizi, Bornstein, Suria 2010; 12
Brain, Williams, Tippins 1985; 313
Llewelyn, Hawkins, Russell 1992; 305
McCarthy, Lawson 1990; 34
Skljarevski, Oakes, Zhang 2018; 75
Mulderry, Ghatei, Spokes 1988; 25
Junghans 1997; 16
Sun, Lu, Joshi 2005; 45
Garg, Balthasar 2009; 11
Webster, Caram-Salas, Haqqani 2016; 30
Mitsikostas, Reuter 2017; 30
Ferri, Bellosta, Baldessin 2016; 111
Wang, Wang, Balthasar 2008; 84
Ho, Edvinsson, Goadsby 2010; 6
Edlund, Melin, Parra-Guillen 2015; 54
Waldmann, Jones 1972; 9
Tabrizi, Tseng, Roskos 2006; 11
Kuang, King, Wang 2010; 2
Aarli, Matre, Thunold 1991; 95
Sarchielli, Alberti, Codini 2000; 20
Finke, Banks 2017; 25
Lee, Kelley, King 2011; 13
Fusayasu, Kowa, Takeshima 2007; 128
Yu, Watts 2013; 10
Berdeja, Jagannath, Zonder 2016; 16
Abuqayyas, Balthasar 2013; 10
Detke, Goadsby, Wang 2018; 90
Schankin, Maniyar, Seo 2016; 139
Cohen-Barak, Weiss, Rasamoelisolo 2018; 38
Lobo, Hansen, Balthasar 2004; 93
Zhang, Pardridge 2001; 114
Ma, Yang, Wang 2009; 49
Fetterly, Aras, Meholick 2013; 53
Stauffer, Dodick, Zhang 2018; 75
Cernuda-Morollon, Larrosa, Ramon 2013; 81
Moss, Brinks, Carpenter 2013; 38
Kimball, Norman, Shield 1995; 3
Hougaard, Amin, Christensen 2017; 140
Oakes, Skljarevski, Zhang 2018; 38
Langmuir, Mendonca, Woo 1992; 52
Muralidharan, Kuesters, Plavina 2017; 57
Wohlrab 2015; 13
Vu, Ma, Chen 2017; 34
Baxter, Zhu, Mackensen 1994; 54
Kohler, Milstein 1975; 256
Goadsby, Edvinsson, Ekman 1990; 28
Meibohm, Zhou 2012; 52
Chen, Hickling, Kraynov 2013; 15
Zhu, Meng, Dickinson 2001; 166
Blum, Phelps, Ank 1981; 15
Roberts, Susano, Gipson 2013; 53
Adams, Schier, McCall 2001; 61
Mager 2006; 72
Xu, Davis, Zhou 2013; 137
Shankar, Shores, Wagner 2006; 24
Hayashi, Tsukamoto, Sallas 2007; 63
Tepper 2018; 58
Kraenzlin, Ch'ng, Mulderry 1985; 10
Covell, Barbet, Holton 1986; 46
Mould, Sweeney 2007; 10
Vargas, Starling, Silberstein 2018; 90: P4.098
Giamberardino, Affaitati, Curto 2016; 11
Hwang, Foote 2005; 36
Shankar, Arkin, Cocea 2014; 16
Lowe, Tannenbaum, Gautier 2009; 68
Juweid, Neumann, Paik 1992; 52
Juhasz, Zsombok, Modos 2003; 106
Flessner, Lofthouse, Zakaria el 1997; 273
Brambell 1966; 2
Zheng, McIntosh, Wang 2015; 55
Skljarevski, Matharu, Millen 2018; 38
Struemper, Chen, Cai 2013; 53
Zhang, Wei, Bajaj 2015; 55
Lowe, Georgiou, Canvin 2015; 71
Marathe, Peterson, Mager 2008; 326
Zhang, Yao, Kaila 2014; 121
Long, Chigutsa, Wallin 2017; 56
Goadsby, Edvinsson 1993; 33
Steenbergh, Hoppener, Zandberg 1985; 183
Raffaelli, Reuter 2018; 15
Schellekens 2005; 20
Wang, Wang, Doddareddy 2014; 16
Chames, Van Regenmortel, Weiss 2009; 157
Xiao, Krzyzanski, Wang 2010; 12
Keizer, Huitema, Schellens 2010; 49
Mahmood, Green 2005; 44
Ober, Martinez, Vaccaro 2004; 172
Blumenthal, Fand, Sharkey 1991; 33
Mould, Meibohm 2016; 30
Davda, Hansen 2010; 2
Spiekermann, Finn, Ward 2002; 196
bibr58-0333102419840780
bibr15-0333102419840780
bibr74-0333102419840780
bibr2-0333102419840780
bibr82-0333102419840780
bibr33-0333102419840780
bibr76-0333102419840780
bibr90-0333102419840780
Langmuir VK (bibr38-0333102419840780) 1992; 52
bibr25-0333102419840780
bibr68-0333102419840780
bibr9-0333102419840780
bibr64-0333102419840780
bibr17-0333102419840780
bibr43-0333102419840780
bibr48-0333102419840780
bibr35-0333102419840780
bibr56-0333102419840780
bibr4-0333102419840780
bibr27-0333102419840780
bibr84-0333102419840780
bibr19-0333102419840780
Waldmann TA (bibr24-0333102419840780) 1972; 9
bibr66-0333102419840780
bibr92-0333102419840780
bibr53-0333102419840780
bibr103-0333102419840780
bibr6-0333102419840780
bibr61-0333102419840780
bibr28-0333102419840780
bibr97-0333102419840780
Mould DR (bibr16-0333102419840780) 2007; 10
bibr52-0333102419840780
bibr95-0333102419840780
bibr89-0333102419840780
Covell DG (bibr29-0333102419840780) 1986; 46
bibr60-0333102419840780
Vargas B (bibr78-0333102419840780) 2018; 90
bibr55-0333102419840780
bibr7-0333102419840780
bibr98-0333102419840780
bibr94-0333102419840780
bibr21-0333102419840780
bibr100-0333102419840780
bibr13-0333102419840780
bibr47-0333102419840780
bibr72-0333102419840780
bibr86-0333102419840780
bibr80-0333102419840780
bibr41-0333102419840780
bibr44-0333102419840780
Frazer JK (bibr20-0333102419840780) 1999
Adams GP (bibr39-0333102419840780) 2001; 61
bibr10-0333102419840780
Flessner MF (bibr31-0333102419840780) 1997; 273
bibr40-0333102419840780
bibr83-0333102419840780
bibr91-0333102419840780
bibr32-0333102419840780
bibr75-0333102419840780
bibr67-0333102419840780
bibr59-0333102419840780
bibr73-0333102419840780
bibr81-0333102419840780
bibr42-0333102419840780
bibr3-0333102419840780
bibr77-0333102419840780
bibr50-0333102419840780
bibr63-0333102419840780
bibr22-0333102419840780
bibr69-0333102419840780
bibr71-0333102419840780
Juweid M (bibr36-0333102419840780) 1992; 52
bibr14-0333102419840780
bibr101-0333102419840780
bibr87-0333102419840780
bibr1-0333102419840780
bibr79-0333102419840780
bibr96-0333102419840780
bibr70-0333102419840780
bibr45-0333102419840780
bibr88-0333102419840780
bibr102-0333102419840780
bibr11-0333102419840780
bibr37-0333102419840780
bibr54-0333102419840780
bibr8-0333102419840780
bibr46-0333102419840780
bibr12-0333102419840780
bibr51-0333102419840780
bibr26-0333102419840780
bibr34-0333102419840780
bibr85-0333102419840780
Wohlrab J (bibr49-0333102419840780) 2015; 13
bibr18-0333102419840780
bibr93-0333102419840780
Baxter LT (bibr30-0333102419840780) 1994; 54
bibr99-0333102419840780
bibr65-0333102419840780
bibr57-0333102419840780
bibr62-0333102419840780
bibr5-0333102419840780
bibr23-0333102419840780
References_xml – volume: 121
  start-page: 2237
  year: 2014
  end-page: 2246
  article-title: Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema
  publication-title: Ophthalmology
– volume: 54
  start-page: 1517
  year: 1994
  end-page: 1528
  article-title: Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice
  publication-title: Cancer Res
– volume: 15
  start-page: 324
  year: 2018
  end-page: 335
  article-title: The biology of monoclonal antibodies: Focus on calcitonin gene-related peptide for prophylactic migraine therapy
  publication-title: Neurotherapeutics
– volume: 72
  start-page: 1
  year: 2006
  end-page: 10
  article-title: Target-mediated drug disposition and dynamics
  publication-title: Biochem Pharmacol
– volume: 15
  start-page: 1256
  year: 1981
  end-page: 1260
  article-title: Survival of oral human immune serum globulin in the gastrointestinal tract of low birth weight infants
  publication-title: Pediatr Res
– volume: 68
  start-page: 61
  year: 2009
  end-page: 76
  article-title: Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma
  publication-title: Br J Clin Pharmacol
– volume: 313
  start-page: 54
  year: 1985
  end-page: 56
  article-title: Calcitonin gene-related peptide is a potent vasodilator
  publication-title: Nature
– volume: 10
  start-page: 189
  year: 1985
  end-page: 197
  article-title: Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones
  publication-title: Regul Pept
– volume: 166
  start-page: 3266
  year: 2001
  end-page: 3276
  article-title: MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells
  publication-title: J Immunol
– volume: 95
  start-page: 64
  year: 1991
  end-page: 69
  article-title: IgG Fc receptors on epithelial cells of distal tubuli and on endothelial cells in human kidney
  publication-title: Int Arch Allergy Appl Immunol
– volume: 30
  start-page: 1927
  year: 2016
  end-page: 1940
  article-title: Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1
  publication-title: FASEB J
– volume: 2
  start-page: 1087
  year: 1966
  end-page: 1093
  article-title: The transmission of immunity from mother to young and the catabolism of immunoglobulins
  publication-title: Lancet
– volume: 46
  start-page: 3969
  year: 1986
  end-page: 3978
  article-title: Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice
  publication-title: Cancer Res
– volume: 75
  start-page: 187
  year: 2018
  end-page: 193
  article-title: Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: A randomized clinical trial
  publication-title: JAMA Neurol
– volume: 36
  start-page: 3
  year: 2005
  end-page: 10
  article-title: Immunogenicity of engineered antibodies
  publication-title: Methods
– volume: 45
  start-page: 468
  year: 2005
  end-page: 476
  article-title: Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects
  publication-title: J Clin Pharmacol
– volume: 11
  start-page: 81
  year: 2006
  end-page: 88
  article-title: Elimination mechanisms of therapeutic monoclonal antibodies
  publication-title: Drug Discov Today
– volume: 273
  start-page: H2783
  year: 1997
  end-page: H2793
  article-title: In vivo diffusion of immunoglobulin G in muscle: Effects of binding, solute exclusion, and lymphatic removal
  publication-title: Am J Physiol
– volume: 56
  start-page: 41
  year: 2017
  end-page: 54
  article-title: Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study
  publication-title: Clin Pharmacokinet
– volume: 114
  start-page: 168
  year: 2001
  end-page: 172
  article-title: Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier
  publication-title: J Neuroimmunol
– volume: 139
  start-page: 1994
  year: 2016
  end-page: 2001
  article-title: Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine
  publication-title: Brain
– volume: 81
  start-page: 1191
  year: 2013
  end-page: 1196
  article-title: Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
  publication-title: Neurology
– volume: 52
  start-page: 5144
  year: 1992
  end-page: 5153
  article-title: Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier
  publication-title: Cancer Res
– volume: 52
  start-page: 4728
  year: 1992
  end-page: 4734
  article-title: Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: Uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids
  publication-title: Cancer Res
– volume: 10
  start-page: 201
  year: 1982
  end-page: 227
  article-title: Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
  publication-title: J Pharmacokinet Biopharm
– volume: 61
  start-page: 4750
  year: 2001
  end-page: 4755
  article-title: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
  publication-title: Cancer Res
– volume: 49
  start-page: 1142
  year: 2009
  end-page: 1156
  article-title: Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors
  publication-title: J Clin Pharmacol
– volume: 16
  start-page: 29
  year: 1997
  end-page: 57
  article-title: Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG
  publication-title: Immunol Res
– volume: 111
  start-page: 592
  year: 2016
  end-page: 599
  article-title: Pharmacokinetics interactions of monoclonal antibodies
  publication-title: Pharmacol Res
– volume: 196
  start-page: 303
  year: 2002
  end-page: 310
  article-title: Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: Functional expression of FcRn in the mammalian lung
  publication-title: J Exp Med
– volume: 56
  start-page: 505
  year: 2017
  end-page: 514
  article-title: Population pharmacokinetics of necitumumab in cancer patients
  publication-title: Clin Pharmacokinet
– volume: 63
  start-page: 548
  year: 2007
  end-page: 561
  article-title: A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
  publication-title: Br J Clin Pharmacol
– volume: 10
  start-page: 1505
  year: 2013
  end-page: 1513
  article-title: Investigation of the role of FcgammaR and FcRn in mAb distribution to the brain
  publication-title: Mol Pharm
– volume: 15
  start-page: 1141
  year: 2013
  end-page: 1154
  article-title: A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics
  publication-title: AAPS J
– volume: 33
  start-page: 48
  year: 1993
  end-page: 56
  article-title: The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
  publication-title: Ann Neurol
– volume: 34
  start-page: 623
  year: 1990
  end-page: 632
  article-title: Cell type and conduction velocity of rat primary sensory neurons with calcitonin gene-related peptide-like immunoreactivity
  publication-title: Neuroscience
– volume: 172
  start-page: 2021
  year: 2004
  end-page: 2029
  article-title: Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
  publication-title: J Immunol
– volume: 12
  start-page: 33
  year: 2010
  end-page: 43
  article-title: Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease
  publication-title: AAPS J
– volume: 30
  start-page: 272
  year: 2017
  end-page: 280
  article-title: Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: Comparisons across randomized controlled studies
  publication-title: Curr Opin Neurol
– volume: 3
  start-page: 212
  year: 1995
  end-page: 221
  article-title: The OKT3 Antibody Response Study: A multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation
  publication-title: Transpl Immunol
– volume: 30
  start-page: 275
  year: 2016
  end-page: 293
  article-title: Drug development of therapeutic monoclonal antibodies
  publication-title: BioDrugs
– volume: 9
  start-page: 5
  year: 1972
  end-page: 23
  article-title: The role of cell-surface receptors in the transport and catabolism of immunoglobulins
  publication-title: Ciba Found Symp
– volume: 157
  start-page: 220
  year: 2009
  end-page: 233
  article-title: Therapeutic antibodies: Successes, limitations and hopes for the future
  publication-title: Br J Pharmacol
– volume: 38
  start-page: 1442
  year: 2018
  end-page: 1454
  article-title: Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
  publication-title: Cephalalgia
– volume: 256
  start-page: 495
  year: 1975
  end-page: 497
  article-title: Continuous cultures of fused cells secreting antibody of predefined specificity
  publication-title: Nature
– volume: 25
  start-page: 131
  year: 2017
  end-page: 146
  article-title: Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy
  publication-title: Hum Antibodies
– volume: 10
  start-page: 84
  year: 2007
  end-page: 96
  article-title: The pharmacokinetics and pharmacodynamics of monoclonal antibodies – mechanistic modeling applied to drug development
  publication-title: Curr Opin Drug Discov Devel
– volume: 84
  start-page: 548
  year: 2008
  end-page: 558
  article-title: Monoclonal antibody pharmacokinetics and pharmacodynamics
  publication-title: Clin Pharmacol Ther
– volume: 10
  start-page: 459
  year: 2013
  end-page: 472
  article-title: Developing therapeutic antibodies for neurodegenerative disease
  publication-title: Neurotherapeutics
– volume: 53
  start-page: 711
  year: 2013
  end-page: 720
  article-title: Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus
  publication-title: J Clin Pharmacol
– volume: 2
  start-page: 1125
  year: 2010
  end-page: 1140
  article-title: Therapeutic monoclonal antibody concentration monitoring: free or total?
  publication-title: Bioanalysis
– volume: 55
  start-page: S75
  year: 2015
  end-page: S84
  article-title: Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development – opportunities and challenges
  publication-title: J Clin Pharmacol
– volume: 75
  start-page: 1080
  year: 2018
  end-page: 1088
  article-title: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial
  publication-title: JAMA Neurol
– volume: 140
  start-page: 1633
  year: 2017
  end-page: 1642
  article-title: Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura
  publication-title: Brain
– volume: 28
  start-page: 183
  year: 1990
  end-page: 187
  article-title: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
  publication-title: Ann Neurol
– volume: 13
  start-page: 530
  year: 2015
  end-page: 534
  article-title: Pharmacokinetic characteristics of therapeutic antibodies
  publication-title: J Dtsch Dermatol Ges
– volume: 34
  start-page: 1784
  year: 2017
  end-page: 1795
  article-title: Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects
  publication-title: Pharm Res
– volume: 52
  start-page: 54S
  year: 2012
  end-page: 62S
  article-title: Characterizing the impact of renal impairment on the clinical pharmacology of biologics
  publication-title: J Clin Pharmacol
– volume: 20
  start-page: vi3
  issue: Suppl 6
  year: 2005
  end-page: 9
  article-title: Factors influencing the immunogenicity of therapeutic proteins
  publication-title: Nephrol Dial Transplant
– volume: 24
  start-page: 274
  year: 2006
  end-page: 280
  article-title: Scientific and regulatory considerations on the immunogenicity of biologics
  publication-title: Trends Biotechnol
– volume: 12
  start-page: 646
  year: 2010
  end-page: 657
  article-title: Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys
  publication-title: AAPS J
– volume: 13
  start-page: 99
  year: 2011
  end-page: 110
  article-title: Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: Technical challenges and PK/PD applications over the course of drug development
  publication-title: AAPS J
– volume: 44
  start-page: 331
  year: 2005
  end-page: 347
  article-title: Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins
  publication-title: Clin Pharmacokinet
– volume: 38
  start-page: 1960
  year: 2018
  end-page: 1971
  article-title: A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
  publication-title: Cephalalgia
– volume: 11
  start-page: 1045
  year: 2016
  end-page: 1057
  article-title: Anti-CGRP monoclonal antibodies in migraine: Current perspectives
  publication-title: Intern Emerg Med
– volume: 90: P4.098
  year: 2018
  article-title: Erenumab immunogenicity: A pooled analysis of Phase 2 and Phase 3 migraine prevention clinical trials (P4.098)
  publication-title: Neurology
– volume: 137
  start-page: 225
  year: 2013
  end-page: 247
  article-title: Rational development and utilization of antibody-based therapeutic proteins in pediatrics
  publication-title: Pharmacol Ther
– volume: 58
  start-page: 238
  year: 2018
  end-page: 275
  article-title: History and review of anti-calcitonin gene-related peptide (CGRP) therapies: From translational research to treatment
  publication-title: Headache
– volume: 20
  start-page: 907
  year: 2000
  end-page: 918
  article-title: Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks
  publication-title: Cephalalgia
– volume: 11
  start-page: 553
  year: 2009
  end-page: 557
  article-title: Investigation of the influence of FcRn on the distribution of IgG to the brain
  publication-title: AAPS J
– volume: 16
  start-page: 129
  year: 2016
  end-page: 138
  article-title: Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: Results of a phase Ib study
  publication-title: Clin Lymphoma Myeloma Leuk
– volume: 38
  start-page: 1015
  year: 2018
  end-page: 1025
  article-title: Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
  publication-title: Cephalalgia
– volume: 53
  start-page: 1020
  year: 2013
  end-page: 1027
  article-title: Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data
  publication-title: J Clin Pharmacol
– volume: 71
  start-page: 68
  year: 2015
  end-page: 77
  article-title: Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE
  publication-title: Regul Toxicol Pharmacol
– volume: 16
  start-page: 658
  year: 2014
  end-page: 673
  article-title: Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations
  publication-title: AAPS J
– volume: 106
  start-page: 461
  year: 2003
  end-page: 470
  article-title: NO-induced migraine attack: Strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release
  publication-title: Pain
– volume: 38
  start-page: 1188
  year: 2013
  end-page: 1197
  article-title: Review article: Immunogenicity of anti-TNF biologics in IBD – the role of patient, product and prescriber factors
  publication-title: Aliment Pharmacol Ther
– volume: 54
  start-page: 35
  year: 2015
  end-page: 80
  article-title: Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children
  publication-title: Clin Pharmacokinet
– volume: 305
  start-page: 1269
  year: 1992
  end-page: 1272
  article-title: Discovery of antibodies
  publication-title: BMJ
– volume: 16
  start-page: 129
  year: 2014
  end-page: 139
  article-title: Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys
  publication-title: AAPS J
– volume: 326
  start-page: 555
  year: 2008
  end-page: 562
  article-title: Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients
  publication-title: J Pharmacol Exp Ther
– volume: 53
  start-page: 919
  year: 2013
  end-page: 924
  article-title: Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease
  publication-title: J Clin Pharmacol
– volume: 57
  start-page: 1017
  year: 2017
  end-page: 1030
  article-title: Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis
  publication-title: J Clin Pharmacol
– volume: 128
  start-page: 209
  year: 2007
  end-page: 214
  article-title: Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods
  publication-title: Pain
– volume: 90
  start-page: e2211
  year: 2018
  end-page: e2221
  article-title: Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
  publication-title: Neurology
– volume: 6
  start-page: 573
  year: 2010
  end-page: 582
  article-title: CGRP and its receptors provide new insights into migraine pathophysiology
  publication-title: Nat Rev Neurol
– volume: 33
  start-page: 351
  year: 1991
  end-page: 358
  article-title: The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: An autoradiographic study
  publication-title: Cancer Immunol Immunother
– volume: 183
  start-page: 403
  year: 1985
  end-page: 407
  article-title: A second human calcitonin/CGRP gene
  publication-title: FEBS Lett
– volume: 93
  start-page: 2645
  year: 2004
  end-page: 2668
  article-title: Antibody pharmacokinetics and pharmacodynamics
  publication-title: J Pharm Sci
– volume: 55
  start-page: S103
  year: 2015
  end-page: S115
  article-title: Challenges and considerations for development of therapeutic proteins in pediatric patients
  publication-title: J Clin Pharmacol
– volume: 25
  start-page: 195
  year: 1988
  end-page: 205
  article-title: Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat
  publication-title: Neuroscience
– volume: 49
  start-page: 493
  year: 2010
  end-page: 507
  article-title: Clinical pharmacokinetics of therapeutic monoclonal antibodies
  publication-title: Clin Pharmacokinet
– volume: 2
  start-page: 576
  year: 2010
  end-page: 588
  article-title: Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets
  publication-title: MAbs
– ident: bibr71-0333102419840780
  doi: 10.1208/s12248-014-9599-2
– ident: bibr13-0333102419840780
  doi: 10.1097/WCO.0000000000000438
– ident: bibr70-0333102419840780
  doi: 10.1016/j.tibtech.2006.04.001
– ident: bibr46-0333102419840780
  doi: 10.1096/fj.201500078
– ident: bibr96-0333102419840780
  doi: 10.1038/nrneurol.2010.127
– ident: bibr103-0333102419840780
  doi: 10.4161/mabs.2.5.12833
– ident: bibr92-0333102419840780
  doi: 10.1111/j.1365-2125.2009.03401.x
– volume: 52
  start-page: 4728
  year: 1992
  ident: bibr38-0333102419840780
  publication-title: Cancer Res
– ident: bibr57-0333102419840780
  doi: 10.1007/s11095-017-2183-6
– ident: bibr73-0333102419840780
  doi: 10.1016/j.pharmthera.2012.10.005
– ident: bibr40-0333102419840780
  doi: 10.1208/s12248-009-9129-9
– ident: bibr51-0333102419840780
  doi: 10.2165/11531280-000000000-00000
– ident: bibr19-0333102419840780
  doi: 10.1208/s12248-010-9222-0
– ident: bibr14-0333102419840780
  doi: 10.1007/s13311-018-0622-7
– ident: bibr22-0333102419840780
  doi: 10.1038/256495a0
– ident: bibr41-0333102419840780
  doi: 10.1016/S0165-5728(01)00242-9
– ident: bibr66-0333102419840780
  doi: 10.1007/s40262-016-0417-0
– ident: bibr64-0333102419840780
  doi: 10.1002/jcph.104
– ident: bibr28-0333102419840780
  doi: 10.1203/00006450-198109000-00006
– ident: bibr69-0333102419840780
  doi: 10.1111/apt.12507
– ident: bibr98-0333102419840780
  doi: 10.1001/jamaneurol.2017.3859
– ident: bibr85-0333102419840780
  doi: 10.1007/s40262-014-0208-4
– ident: bibr33-0333102419840780
  doi: 10.1002/jps.20178
– ident: bibr52-0333102419840780
  doi: 10.1016/S0140-6736(66)92190-8
– ident: bibr101-0333102419840780
– ident: bibr10-0333102419840780
– ident: bibr9-0333102419840780
  doi: 10.1016/0167-0115(85)90013-8
– ident: bibr32-0333102419840780
– ident: bibr65-0333102419840780
  doi: 10.1016/j.ophtha.2014.05.012
– ident: bibr44-0333102419840780
  doi: 10.1007/s13311-013-0187-4
– ident: bibr60-0333102419840780
  doi: 10.4155/bio.10.64
– ident: bibr18-0333102419840780
  doi: 10.1208/s12248-013-9545-8
– ident: bibr47-0333102419840780
  doi: 10.1093/brain/awx089
– ident: bibr55-0333102419840780
  doi: 10.2165/00003088-200544040-00001
– volume: 9
  start-page: 5
  year: 1972
  ident: bibr24-0333102419840780
  publication-title: Ciba Found Symp
– ident: bibr67-0333102419840780
  doi: 10.1016/j.clml.2015.12.007
– volume: 61
  start-page: 4750
  year: 2001
  ident: bibr39-0333102419840780
  publication-title: Cancer Res
– ident: bibr102-0333102419840780
– ident: bibr27-0333102419840780
  doi: 10.1084/jem.20020400
– ident: bibr77-0333102419840780
  doi: 10.1177/0333102418779543
– ident: bibr48-0333102419840780
  doi: 10.1093/brain/aww096
– ident: bibr2-0333102419840780
  doi: 10.1038/313054a0
– ident: bibr58-0333102419840780
  doi: 10.1124/jpet.108.137703
– ident: bibr74-0333102419840780
  doi: 10.1208/s12248-013-9517-z
– ident: bibr56-0333102419840780
  doi: 10.1016/j.bcp.2005.12.041
– ident: bibr90-0333102419840780
  doi: 10.1002/jcph.357
– ident: bibr89-0333102419840780
  doi: 10.1111/j.1476-5381.2009.00190.x
– ident: bibr53-0333102419840780
  doi: 10.4049/jimmunol.172.4.2021
– ident: bibr1-0333102419840780
  doi: 10.1111/head.13379
– ident: bibr76-0333102419840780
  doi: 10.1001/jamaneurol.2018.1212
– volume: 54
  start-page: 1517
  year: 1994
  ident: bibr30-0333102419840780
  publication-title: Cancer Res
– ident: bibr63-0333102419840780
  doi: 10.1002/jcph.121
– ident: bibr86-0333102419840780
  doi: 10.1007/BF01062336
– ident: bibr88-0333102419840780
  doi: 10.1208/s12248-011-9251-3
– volume: 46
  start-page: 3969
  year: 1986
  ident: bibr29-0333102419840780
  publication-title: Cancer Res
– ident: bibr80-0333102419840780
  doi: 10.1177/0091270004272731
– ident: bibr84-0333102419840780
  doi: 10.1002/jcph.382
– ident: bibr68-0333102419840780
  doi: 10.1016/j.ymeth.2005.01.001
– ident: bibr21-0333102419840780
  doi: 10.1136/bmj.305.6864.1269
– ident: bibr37-0333102419840780
  doi: 10.1007/BF01741594
– ident: bibr82-0333102419840780
  doi: 10.1002/jcph.894
– ident: bibr17-0333102419840780
  doi: 10.1002/jcph.140
– volume: 52
  start-page: 5144
  year: 1992
  ident: bibr36-0333102419840780
  publication-title: Cancer Res
– ident: bibr94-0333102419840780
  doi: 10.1002/ana.410330109
– volume: 13
  start-page: 530
  year: 2015
  ident: bibr49-0333102419840780
  publication-title: J Dtsch Dermatol Ges
– ident: bibr81-0333102419840780
  doi: 10.1177/0091270009344989
– ident: bibr26-0333102419840780
  doi: 10.1159/000235456
– ident: bibr42-0333102419840780
  doi: 10.1021/mp300214k
– ident: bibr15-0333102419840780
– ident: bibr6-0333102419840780
  doi: 10.1016/j.pain.2006.09.017
– ident: bibr91-0333102419840780
  doi: 10.1111/j.1365-2125.2006.02803.x
– ident: bibr7-0333102419840780
  doi: 10.1046/j.1468-2982.2000.00146.x
– ident: bibr34-0333102419840780
  doi: 10.1002/9783527609628.ch3
– ident: bibr50-0333102419840780
  doi: 10.1016/j.phrs.2016.07.015
– ident: bibr83-0333102419840780
  doi: 10.1007/s40262-016-0452-x
– ident: bibr45-0333102419840780
  doi: 10.3233/HAB-160306
– ident: bibr54-0333102419840780
  doi: 10.1016/S1359-6446(05)03638-X
– ident: bibr62-0333102419840780
  doi: 10.1007/s40259-016-0181-6
– ident: bibr12-0333102419840780
  doi: 10.1007/s11739-016-1489-4
– volume: 10
  start-page: 84
  year: 2007
  ident: bibr16-0333102419840780
  publication-title: Curr Opin Drug Discov Devel
– ident: bibr87-0333102419840780
  doi: 10.1016/j.yrtph.2014.12.002
– ident: bibr59-0333102419840780
  doi: 10.1002/9783527609628.ch12
– ident: bibr11-0333102419840780
– start-page: 37
  volume-title: Fundamental Immunology
  year: 1999
  ident: bibr20-0333102419840780
– ident: bibr72-0333102419840780
  doi: 10.1093/ndt/gfh1092
– ident: bibr100-0333102419840780
  doi: 10.1212/WNL.0000000000006640
– ident: bibr35-0333102419840780
  doi: 10.1038/clpt.2008.170
– ident: bibr23-0333102419840780
  doi: 10.1007/BF02786322
– volume: 273
  start-page: H2783
  year: 1997
  ident: bibr31-0333102419840780
  publication-title: Am J Physiol
– volume: 90
  year: 2018
  ident: bibr78-0333102419840780
  publication-title: Neurology
– ident: bibr4-0333102419840780
  doi: 10.1016/0014-5793(85)80820-6
– ident: bibr5-0333102419840780
  doi: 10.1016/0306-4522(88)90018-8
– ident: bibr25-0333102419840780
  doi: 10.4049/jimmunol.166.5.3266
– ident: bibr75-0333102419840780
  doi: 10.1016/0966-3274(95)80027-1
– ident: bibr99-0333102419840780
  doi: 10.1177/0333102417747230
– ident: bibr43-0333102419840780
  doi: 10.1212/WNL.86.16_supplement.S26.007
– ident: bibr8-0333102419840780
  doi: 10.1016/j.pain.2003.09.008
– ident: bibr97-0333102419840780
  doi: 10.1212/WNL.0b013e3182a6cb72
– ident: bibr93-0333102419840780
  doi: 10.1208/s12248-009-9157-5
– ident: bibr61-0333102419840780
  doi: 10.1177/0091270011413894
– ident: bibr3-0333102419840780
  doi: 10.1016/0306-4522(90)90169-5
– ident: bibr79-0333102419840780
  doi: 10.1177/0333102418771376
– ident: bibr95-0333102419840780
  doi: 10.1002/ana.410280213
SSID ssj0005606
Score 2.4902084
SecondaryResourceType review_article
Snippet Purpose To review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin...
To review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin gene-related...
SourceID pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1284
SubjectTerms Review
Title A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
URI https://journals.sagepub.com/doi/full/10.1177/0333102419840780
https://www.ncbi.nlm.nih.gov/pubmed/30917684
https://www.proquest.com/docview/2199184718
https://pubmed.ncbi.nlm.nih.gov/PMC6710614
Volume 39
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEB_qFcSX4nejbVlBBMF4aTZf60u5Vs8iVEppsW9hv6JHe0lpkof6b_QfdibZXD0Pxbd8zCZhZjfz2_3NzgC8lgRzQxP7lJrFj3aN9IXR0o9Ty1WcZDZLaYPz0dfk8Cz6ch6fr0E57IVxGqzfU1gVflH3s6bRTavRY0cyjgPOEZag8xEZ8VDBXtvM8361eyiqQVeInm7nxGxrioe88YfdbfdgPUyTOBzB-mR68u30LigkCXp2k1PEVhjdEZsr71x2ZCvodDXI8rdIsc55TR_ChkOdbNJ3k0ewZsvHcP_I8epP4HbCEF4zey0Zglg2n32nyhH2Azt2ma0v8AzbMlkaduWumb6YPZuVNc3wazxoKoZaqfQl4XsUbmaqojBFRsu9jB6u25pVJUO_hDa1P9u5VO9QsJP1Dz6fHA-tbp7C2fTT6cGh78o1-DriUeNzLTVaVtq4EEIbo4iRlNrISFichVsRSIUSOiokKlAVCSInBICqMDooCsH5MxiVVWk3gYUap7XGZKqIFOK9TJpYYMNERoXhIhAejAfd59rlMqeSGpf57pC-_A9refB20eKqz-PxD9lXgzlzHGzEoKBGqrbOQwoU6_y5B8978y6exhF5EavpQbpk-IUAJfJevlPOfnQJvZO0m5h78Ia6SD6Mgb9-4Iv_FXwJDxDguZi4LRg1163dRhDVqB3s-fsf96c7bgT8Ah1yGY4
linkProvider SAGE Publications
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEB1VqQS8IO6Y6yIBEhIurr12vEg8RIWQ0qaqqlT0zezNbURjV7UjFH6Dr-AvmXHWKSEC8dK3xJndrHZ2ds7sHM8CPJcEc0MT-1SaxeebRvrCaOnHXRupOElt2qUXnId7yeCQfzqKj9bgZ_sujJvBaoNoVTiiZrNeWDdVSooiRCTod0RKKajA8Sl37OwbRmvVu-33qNoXYdj_MNoa-O5CAV_ziNd-pKXG_5Y2zoXQxijKmUltJBcW40QrAqlQQvNcYt8qT9C3I0RRudFBngs6-8Tdfp3HuPF3YL3XP_g8uuCTJME8MRoR2SvkFznRlTEv-8AVYLvKz_yNZNb4vf4NuO4AK-vNV9hNWLPFLbgydCn52_CjxxCZM3suGeJfNhkf06UT9i3bd0Wxv-I3bMtkYdiZe2ZmhZzgs3FR0eFAhR_qkqFFlPqUQgMUrseqJIYjo5NiRp3racXKgqFLw-Vgv08nUr1GwUbW3_p4sN-2mt2Bw0tRzF3oFGVh7wMLNUbExqQq5wqhYipNLLBhInluIhEID960c59pVwadbuM4zTbbyud_aMuDV4sWZ_MSIP-QfdaqM0M7peQLzkg5rbKQOGYNFPDg3ly9i94iBG2UEPWgu6T4hQDVAF_-pRifNLXAk24T03vwkpZI1prPXwf44H8Fn8LVwWi4m-1u7-08hGuIEx217hF06vOpfYxYrFZPnBUw-HLZhvcLSipCWg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEB1VqVTxgrhjrosESEiYuPba8SLxELWEltIqqlrRN7M306iNHdWOUPgNvoN_ZMZZp4QIxEvfEmd2vdnZ8ZzZOZ4FeC4J5oYm9qk0i883jfSF0dKPezZScZLatEcvOO8fJDvH_ONJfLIGP9t3YdwMVm-IVoUjah7WZN0Tk3ddjrEbRBGiEvQ9IqU0VOA4lXt29g0jturd7jaq90UYDt4fbe347lABX_OI136kpcb7SxvnQmhjFOXNpDaSC4uxohWBVCiheS6xb5Un6N8Rpqjc6CDPBe1_4hN_nXP8ix1Y7w8OPx9dckqSYJ4cjYjwFfLLvOjKmJf94Aq4XeVo_kY0a3zf4AZcd6CV9eer7Cas2eIWbOy7tPxt-NFniM6ZvZAMMTAbj77SwRP2LRu6wthn-A3bMlkYNnHXzKyQY7w2KiraIKjwQ10ytIpSn1N4gML1SJXEcmS0W8yocz2tWFkwdGu4JOz36Viq1yjYyPpbHw6HbavZHTi-EsXchU5RFvY-sFBjVGxMqnKuEC6m0sQCGyaS5yYSgfCg2859pl0pdDqR4zzbbKuf_6EtD14tWkzmZUD-IfusVWeGtkoJGJyRclplIfHMGjjgwb25ehe9RQjcKCnqQW9J8QsBqgO-_EsxOm3qgSe9Jq734CUtkaw1ob8O8MH_Cj6FjeH2IPu0e7D3EK4hVHTsukfQqS-m9jHCsVo9cUbA4MtV290vM6JDcw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+new+era+for+migraine%3A+Pharmacokinetic+and+pharmacodynamic+insights+into+monoclonal+antibodies+with+a+focus+on+galcanezumab%2C+an+anti-CGRP+antibody&rft.jtitle=Cephalalgia&rft.au=Kielbasa%2C+William&rft.au=Helton%2C+Danielle+L&rft.date=2019-09-01&rft.issn=0333-1024&rft.eissn=1468-2982&rft.volume=39&rft.issue=10&rft.spage=1284&rft.epage=1297&rft_id=info:doi/10.1177%2F0333102419840780&rft.externalDBID=n%2Fa&rft.externalDocID=10_1177_0333102419840780
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0333-1024&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0333-1024&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0333-1024&client=summon